Login to Your Account



Clinic Roundup


Thursday, February 9, 2012
• GlobeImmune Inc., of Louisville, Colo., said it started a Phase I trial of GI-6301 , a Targmogen candidate, in patients with metastatic cancers containing brachyury protein, which is overexpressed in tumor types such as breast, colon, lung and prostate cancers.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription